Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02361203
Other study ID # 2014-12-0037
Secondary ID
Status Completed
Phase N/A
First received January 29, 2015
Last updated February 1, 2016
Start date February 2015
Est. completion date January 2016

Study information

Verified date February 2016
Source University of Texas at Austin
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether aerobic exercise can enhance the effects of exposure therapy treatment for fear of heights.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date January 2016
Est. primary completion date January 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 25 Years
Eligibility Inclusion Criteria:

- Age 18 to 25

- Speaks English fluently

- Score of 80 or higher on the Acrophobia Questionnaire

- SUDS rating of 50 or higher on the Behavioral Avoidance Test or complete refusal to comply with instructions due to intensity of fear

- Passes the Physical Activity Readiness Questionnaire-Plus

Exclusion Criteria:

- Hearing or visually impaired

- Currently receiving exposure-based treatment for acrophobia

- Able to remain on floor 20 for 30 seconds during BAT with a SUDS rating < 50

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label


Related Conditions & MeSH terms


Intervention

Behavioral:
Exercise
30 minutes of aerobic exercise on a treadmill at 80% of participant's heart rate reserve.

Locations

Country Name City State
United States University of Texas at Austin Austin Texas

Sponsors (1)

Lead Sponsor Collaborator
University of Texas at Austin

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fear scores Change in fear scores using subjective units of distress will be assessed. 7 (+/- 3) days after exposure therapy No
Primary Perceived threat likelihood scores Change in the perception of threat likelihood on a scale from 1-5 will be assessed. 7 (+/- 3) days after exposure therapy No
Secondary Skin conductance fluctuations Changes in skin conductance fluctuations will be assessed. 7 (+/- 3) days after exposure therapy No
Secondary Heart rate fluctuations Heart rate fluctuations will be assessed. 7 (+/- 3) days after exposure therapy No
Secondary Acrophobia Severity Change in score on the Acrophobia Questionnaire 14 (+/- 3) days after exposure therapy No
Secondary Attitudes Toward Heights Change in score on the Attitudes Toward Heights Inventory 14 (+/- 3) days after exposure therapy No
Secondary Clinical Global Improvement Change in score on the Clinical Global Improvement Scale 14 (+/- 3) days after exposure therapy No
See also
  Status Clinical Trial Phase
Completed NCT04003753 - Efficacy of a VR Paradigm to Reduce Fear of Heights in a Clinical and Subclinical Population With Fear of Heights N/A
Completed NCT00302978 - Changes in Brain Activity (Functional MRI Study) Before and After Behavioral Therapy of Height Phobia N/A
Completed NCT03907345 - Generalized Fear Extinction to Untreated Fear Stimuli in Specific Phobias After Exposure N/A
Enrolling by invitation NCT05824884 - Self-efficacy Enhancement in a Virtual Reality Training for Fear of Heights N/A
Completed NCT04737915 - Virtual Reality Exposure Versus In Vivo Exposure for Fear of Heights N/A
Completed NCT04975854 - Virtual Reality Exposure Therapy for Acrophobia N/A
Suspended NCT03917433 - Augmenting Virtual Reality Exposure Therapy for Acrophobia N/A